Quick Comparison

Citicoline (CDP-Choline)Magnesium L-Threonate
Half-Life56-71 hours (sustained release characteristics)2-3 hours (threonate carrier), but brain magnesium levels increase cumulatively
Typical DosageStandard: 250-500 mg daily. Clinical studies use 500-2000 mg daily. Take in the morning — mildly stimulating. Cognizin is the most studied form. Can be split into 2 doses. Often combined with racetams to provide the choline needed for enhanced acetylcholine turnover.Standard: 1500-2000 mg Magnesium L-Threonate daily (providing 144 mg elemental magnesium). Often split into a daytime dose and a pre-bed dose. The Magtein brand uses 2000 mg daily (667 mg three times).
AdministrationOral (capsules, powder). Cognizin branded form is most studied. Take in the morning.Oral (capsules, powder). The L-threonate form is specifically chosen for brain penetration.
Research Papers10 papers10 papers
Categories

Mechanism of Action

Citicoline (CDP-Choline)

Citicoline (CDP-choline) is hydrolyzed in the gut by alkaline phosphatase to choline and cytidine-5'-monophosphate, which are absorbed separately and reassembled in the brain via the Kennedy pathway. Choline feeds two critical pathways: (1) Acetylcholine synthesis via choline acetyltransferase (ChAT) — the primary memory and learning neurotransmitter acting at muscarinic and nicotinic receptors. (2) Phosphatidylcholine synthesis via CTP:phosphocholine cytidylyltransferase — the structural component of neuronal membranes and synaptic vesicles. Cytidine is dephosphorylated to uridine, converted to UTP, and supports RNA synthesis and CDP-choline formation for synapse formation. Citicoline also activates SIRT1 (possibly via NAD+ modulation) and increases brain norepinephrine and dopamine (mechanism unclear — may enhance synthesis or release). It is the only choline source providing both cholinergic and membrane-building support in one molecule.

Magnesium L-Threonate

The L-threonate carrier forms stable complexes with magnesium and transports it across the blood-brain barrier via specific transporters more effectively than inorganic magnesium salts or other chelated forms. Once in the brain, magnesium acts as a voltage-dependent blocker of the NMDA receptor channel at the physiological magnesium binding site within the ion pore, preventing excessive calcium influx and glutamate-mediated excitotoxicity. Magnesium also serves as a cofactor for over 300 enzymes including those involved in neurotransmitter synthesis (tyrosine hydroxylase, glutamic acid decarboxylase), ATP production (creatine kinase, pyruvate kinase), and DNA/RNA polymerase. Elevated brain magnesium enhances synaptic density and plasticity in the hippocampus and prefrontal cortex, likely through CREB-mediated gene expression and increased density of postsynaptic AMPA receptors.

Risks & Safety

Citicoline (CDP-Choline)

Common

Headache (especially with racetams — indicates too much cholinergic stimulation), nausea, diarrhea.

Serious

None documented at standard doses.

Rare

Insomnia, blurred vision.

Magnesium L-Threonate

Common

Drowsiness (often desired for sleep), mild headache initially, gastrointestinal discomfort.

Serious

None documented at standard doses. Magnesium toxicity is not a concern with oral supplementation in people with normal kidney function.

Rare

Diarrhea (less common than with other magnesium forms).

Full Profiles